

Risk for acute myocardial infarction not increased with two-dose HepB-CpG vaccine

April 1 2022



The rate of type 1 acute myocardial infarction (MI) is not increased with



receipt of the two-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) versus the three-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine), according to a study published online March 25 in the *Journal of the American Medical Association*.

Katia Bruxvoort, Ph.D., from the University of Alabama at Birmingham, and colleagues conducted a prospective cohort noninferiority study to compare the rate of acute MI between recipients of the HepB-CpG vaccine (31,183 individuals) and HepB-alum vaccine (38,442 individuals). Participants were followed for 13 months after the index dose.

After inverse probability of treatment weighting, the characteristics were well-balanced between the vaccine groups. The researchers identified 52 type 1 acute MI events among recipients of HepB-CpG vaccine and 71 type 1 acute MI events among recipients of HepB-alum vaccine, for rates of 1.67 and 1.86 per 1,000 person-years, respectively (absolute rate difference, -0.19; adjusted hazard ratio, 0.92, which was below the noninferiority margin).

"Further research is needed to determine if individuals would be more likely to initiate a shorter two-dose series than a longer three-dose series, as well as to address vaccine hesitancy and other barriers to hepatitis B vaccine uptake among adults," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Dynavax Technologies, which manufactures HEPLISAV-B and funded the study.

More information: Katia Bruxvoort et al, Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction, *JAMA* (2022). DOI: 10.1001/jama.2022.2540



© 2022 <u>HealthDay</u>. All rights reserved.

Citation: Risk for acute myocardial infarction not increased with two-dose HepB-CpG vaccine (2022, April 1) retrieved 30 April 2024 from https://medicalxpress.com/news/2022-04-acute-myocardial-infarction-two-dose-hepb-cpg.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.